---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-25-000049"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:52:48.488562+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Centessa Q4 net loss widens to $111.3M; cash $482M; OX2R pipeline on track for 2025 data

## Summary
- Net loss $111.3M in Q4 2024 vs $36.8M Q4 2023, full-year loss $235.8M.
- R&D expenses $60.9M Q4 2024 included $31.5M one-time charge from SerpinPC discontinuation.
- Cash, equivalents and short-term investments $482.2M as of Dec 31, 2024; expected to fund into mid-2027.
- ORX750 Phase 2a CRYSTAL-1 data in NT1, NT2, and IH expected in 2025; Phase 1 data showed restored wakefulness.
- ORX142 and ORX489 advancing in IND-enabling studies with clinical data expected in 2025.

## SEC filing metadata
- accession: 0001847903-25-000049
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000049/0001847903-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000049/cnta-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-25-000049
- JSON: https://secwatch.observer/filing/0001847903-25-000049.json
- Plain text: https://secwatch.observer/filing/0001847903-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.